Relapsed or refractory aggressive non-Hodgkin lymphoma
Conditions
Interventions
None listed
Sponsors
Kato Koji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients scheduled to receive Mosun+Pola combination therapy as part of routine treatment for relapsed or refractory aggressive B-cell lymphoma, based on the latest electronic package inserts for mosnetuzumab and polatuzumab vedotin. The indications based on the latest electronic package inserts are as follows: Relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high-grade B-cell lymphoma) Relapsed or refractory follicular lymphoma (Grade 3B) 2) Patients who have received sufficient explanation about the content of this study, and have obtained written consent from the patient themselves. 3) Patients aged 18 years or older at the time of obtaining informed consent.
Exclusion criteria
Exclusion criteria: Patients who meet the following criteria will be excluded from this clinical study: 1) Patients who, in the opinion of the principal investigator or subinvestigator, are not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Progression free survival (PFS) 2) Overall response rate (ORR), Complete response rate (CRR) 3) End of treatment-overall response rate (EOT-ORR), End of treatment complete response rate (EOT-CRR) 4) Duration of response (DOR), Duration of complete response (DOCR) 5) Adverse Event incidence rate and severity 6) Interruption of treatment due to adverse events, dose reduction, relative dose intensity (RDI) 7) Subgroups analysis of efficacy and safety in elderly subgroup | — |
Contacts
Public ContactKoji Kato
Kyushu University Hospital
Outcome results
None listed